Cybin (HELP.NE) Stock Price

Cybin Price

NYSE AMEX·CLOSED
15.88
​
Market closed

Analysts set a median price target of 22.44 CAD, implying 41.3% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Cybin stock price

Access this data via the Eulerpool API

Cybin business model & stock analysis

Cybin, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. The company has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Frequently asked questions about Cybin

Analysts currently set an average price target of 22.44 CAD for the Cybin stock (median: 22.44 CAD), implying +41.3 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Cybin stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Cybin share trades at 9.95 EUR (15.88 CAD).

The Cybin share (HELP.NE) is listed on 6 stock exchanges, including: Frankfurt (R7E1.F), München (R7E1.MU), Düsseldorf (R7E1.DU), Hamburg (R7E1.HM).

The revenue cannot currently be calculated for Cybin.

The profit of Cybin is -210.92 M CAD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cybin is currently -3.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cybin stock.

The P/S cannot be calculated for Cybin currently.

The Eulerpool Quality Score for Cybin is 2/10.

The ISIN of Cybin is CA23256X4075. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cybin is A2QJAV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cybin is HELP.NE. The ticker symbol is used to trade Cybin shares on the stock exchange.

Fair ValueTerminal
14.29 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cybin.com
Country
Currency
CAD
Initial public offering
Jan 5, 2018
ISIN
CA23256X4075
Cusip
23256X100
Market capitalization
794.64 M CADSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-4.41
P/Ee 2028
-6.46
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
2.41
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-63.85 %
Last updated Oct 10, 2026, 9:23 AM

Cybin Peer Group

Cybin Ticker

AMEX · CYBNDÜSSELDORF · R7E1.DUFRANKFURT · R7E1.FHAMBURG · R7E1.HMMUNICH · R7E1.MUNEO · CYBN.NE

All fundamentals and in-depth analysis of Cybin

Our stock analysis for Cybin stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cybin. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.